{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:44:25Z","timestamp":1790837065055,"version":"4.1.0"},"reference-count":41,"publisher":"American Society of Hematology","issue":"2","license":[{"start":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T00:00:00Z","timestamp":1695945600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,1,23]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Hemophilia B (HB) is caused by an inherited deficiency of plasma coagulation factor IX (FIX). Approximately 60% of pediatric patients with HB possess a severe form of FIX deficiency (&amp;lt;1% FIX activity). Treatment typically requires replacement therapy through the administration of FIX. However, exogenous FIX has a limited functional half-life, and the natural anticoagulant protein S (PS) inhibits activated FIX (FIXa). PS ultimately limits thrombin formation, which limits plasma coagulation. This regulation of FIXa activity by PS led us to test whether inhibiting PS would extend the functional half-life of FIX and thereby prolong FIX-based HB therapy. We assayed clotting times and thrombin generation to measure the efficacy of a PS antibody for increasing FIX activity in commercially obtained plasma and plasma from pediatric patients with HB. We included 11 pediatric patients who lacked additional comorbidities and coagulopathies. In\u00a0vivo, we assessed thrombus formation in HB mice in the presence of the FIXa\u00a0\u00b1 PS antibody. We found an accelerated rate of clotting in the presence of PS antibody. Similarly, the peak thrombin formed was significantly greater in the presence of the PS antibody, even in plasma from patients with severe HB. Furthermore, HB mice injected with PS antibody and FIX had a 4.5-fold higher accumulation of fibrin at the thrombus induction site compared with mice injected with FIX alone. Our findings imply that a PS antibody would be a valuable adjunct to increase the effectiveness of FIX replacement therapy in pediatric patients who have mild, moderate, and severe HB.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2023010819","type":"journal-article","created":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T17:10:28Z","timestamp":1696007428000},"page":"441-452","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":6,"title":["Protein S antibody as an adjunct therapy for hemophilia B"],"prefix":"10.1182","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8904-3338","authenticated-orcid":false,"given":"Hope P.","family":"Wilson","sequence":"first","affiliation":[{"name":"1Department of Biochemistry and Molecular Biology, Louisiana State University Health Sciences Center, New Orleans, LA"},{"name":"2Department of Pediatric Hematology and Oncology, University of Alabama at Birmingham, Birmingham, AL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aliyah","family":"Pierre","sequence":"additional","affiliation":[{"name":"1Department of Biochemistry and Molecular Biology, Louisiana State University Health Sciences Center, New Orleans, LA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley L.","family":"Paysse","sequence":"additional","affiliation":[{"name":"1Department of Biochemistry and Molecular Biology, Louisiana State University Health Sciences Center, New Orleans, LA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narender","family":"Kumar","sequence":"additional","affiliation":[{"name":"1Department of Biochemistry and Molecular Biology, Louisiana State University Health Sciences Center, New Orleans, LA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian C.","family":"Cooley","sequence":"additional","affiliation":[{"name":"3Department of Biochemistry and Biophysics, University of North Carolina, Chapel Hill, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1089-7283","authenticated-orcid":false,"given":"Pratyadipta","family":"Rudra","sequence":"additional","affiliation":[{"name":"4Department of Statistics, Oklahoma State University, Stillwater, OK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrianne W.","family":"Dorsey","sequence":"additional","affiliation":[{"name":"1Department of Biochemistry and Molecular Biology, Louisiana State University Health Sciences Center, New Orleans, LA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7846-2948","authenticated-orcid":false,"given":"Diana","family":"Polania-Villanueva","sequence":"additional","affiliation":[{"name":"1Department of Biochemistry and Molecular Biology, Louisiana State University Health Sciences Center, New Orleans, LA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabyasachi","family":"Chatterjee","sequence":"additional","affiliation":[{"name":"1Department of Biochemistry and Molecular Biology, Louisiana State University Health Sciences Center, New Orleans, LA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maissaa","family":"Janbain","sequence":"additional","affiliation":[{"name":"5Department of Hematology & Medical Oncology, Tulane University, New Orleans, LA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-9426-4075","authenticated-orcid":false,"given":"Maria C.","family":"Velez","sequence":"additional","affiliation":[{"name":"6Department of Pediatric Hematology and Oncology, Children's Hospital of New Orleans, New Orleans, LA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rinku","family":"Majumder","sequence":"additional","affiliation":[{"name":"1Department of Biochemistry and Molecular Biology, Louisiana State University Health Sciences Center, New Orleans, LA"},{"name":"7Department of Interdisciplinary Oncology, Louisiana State University Health Sciences Center, New Orleans, LA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,1,12]]},"reference":[{"issue":"23","key":"2024011922220674000_bib1","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1056\/NEJM200106073442307","article-title":"The hemophilias--from royal genes to gene therapy","volume":"344","author":"Mannucci","year":"2001","journal-title":"N\u00a0Engl J Med"},{"issue":"9371","key":"2024011922220674000_bib2","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1016\/S0140-6736(03)13405-8","article-title":"Haemophilias A and B","volume":"361","author":"Bolton-Maggs","year":"2003","journal-title":"Lancet"},{"issue":"6","key":"2024011922220674000_bib3","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1093\/ajcp\/99.6.687","article-title":"Age-dependent effect on the level of factor IX","volume":"99","author":"Sweeney","year":"1993","journal-title":"Am J Clin Pathol"},{"issue":"22","key":"2024011922220674000_bib4","doi-asserted-by":"crossref","first-page":"3568","DOI":"10.1182\/blood-2013-07-498261","article-title":"Molecular approaches for improved clotting factors for hemophilia","volume":"122","author":"Kaufman","year":"2013","journal-title":"Blood"},{"issue":"14","key":"2024011922220674000_bib5","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1517\/14656566.2012.721780","article-title":"Haemophilia B: current pharmacotherapy and future directions","volume":"13","author":"Franchini","year":"2012","journal-title":"Expert Opin Pharmacother"},{"issue":"13","key":"2024011922220674000_bib6","doi-asserted-by":"crossref","first-page":"3600","DOI":"10.1182\/blood.V98.13.3600","article-title":"Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates","volume":"98","author":"Roth","year":"2001","journal-title":"Blood"},{"issue":"31","key":"2024011922220674000_bib7","doi-asserted-by":"crossref","first-page":"28686","DOI":"10.1074\/jbc.M101813200","article-title":"Channeling during prothrombin activation","volume":"276","author":"Boskovic","year":"2001","journal-title":"J\u00a0Biol Chem"},{"issue":"4","key":"2024011922220674000_bib8","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/S0002-9378(99)70335-2","article-title":"Preeclampsia and genetic risk factors for thrombosis: a case-control study","volume":"181","author":"De Groot","year":"1999","journal-title":"Am J Obstet Gynecol"},{"issue":"4","key":"2024011922220674000_bib9","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1182\/blood-2003-05-1551","article-title":"Coagulation, inflammation, and apoptosis: different roles for protein S and the protein S-C4b binding protein complex","volume":"103","author":"Rezende","year":"2004","journal-title":"Blood"},{"issue":"4","key":"2024011922220674000_bib10","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1055\/s-2007-1002683","article-title":"Neonatal purpura fulminans due to homozygous protein C or protein S deficiencies","volume":"16","author":"Marlar","year":"1990","journal-title":"Semin Thromb Hemost"},{"issue":"5","key":"2024011922220674000_bib11","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/S0022-3476(05)83335-9","article-title":"Homozygous protein S deficiency in an infant with purpura fulminans","volume":"117","author":"Mahasandana","year":"1990","journal-title":"J\u00a0Pediatr"},{"issue":"5","key":"2024011922220674000_bib12","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1172\/JCI117883","article-title":"Protein S as an in\u00a0vivo cofactor to activated protein C in prevention of microarterial thrombosis in rabbits","volume":"95","author":"Arnljots","year":"1995","journal-title":"J\u00a0Clin Invest"},{"issue":"1","key":"2024011922220674000_bib13","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1182\/blood.V69.1.231.231","article-title":"Protein S is a cofactor for activated protein C neutralization of an inhibitor of plasminogen activation released from platelets","volume":"69","author":"D'Angelo","year":"1987","journal-title":"Blood"},{"issue":"9","key":"2024011922220674000_bib14","doi-asserted-by":"crossref","first-page":"3106","DOI":"10.1073\/pnas.0504240103","article-title":"Protein S stimulates inhibition of the tissue factor pathway by tissue factor pathway inhibitor","volume":"103","author":"Hackeng","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2024011922220674000_bib15","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1111\/j.1538-7836.2008.02980.x","article-title":"Protein S enhances the tissue factor pathway inhibitor inhibition of factor Xa but not its inhibition of factor VIIa\u2013tissue factor","volume":"6","author":"Ndonwi","year":"2008","journal-title":"J\u00a0Thromb Haemost"},{"issue":"10","key":"2024011922220674000_bib16","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1161\/ATVBAHA.112.250928","article-title":"Inhibition of intrinsic Xase by protein S: a novel regulatory role of protein S independent of activated protein C","volume":"32","author":"Chattopadhyay","year":"2012","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"4","key":"2024011922220674000_bib17","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1161\/ATVBAHA.117.310588","article-title":"Anticoagulant protein S targets the factor IXa heparin-binding exosite to prevent thrombosis","volume":"38","author":"Plautz","year":"2018","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2024011922220674000_bib18","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.thromres.2018.08.018","article-title":"Padua FIXa resistance to protein S and a potential therapy for hyperactive FIXa","volume":"170","author":"Plautz","year":"2018","journal-title":"Thromb Res"},{"issue":"6","key":"2024011922220674000_bib19","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/S0889-8588(18)30207-7","article-title":"Current management of hemophilia B","volume":"7","author":"Roberts","year":"1993","journal-title":"Hematol Oncol Clin North Am"},{"issue":"4","key":"2024011922220674000_bib20","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1111\/j.1365-2516.2001.00534.x","article-title":"Barriers to compliance with prophylaxis therapy in haemophilia","volume":"7","author":"Hacker","year":"2001","journal-title":"Haemophilia"},{"issue":"suppl 1","key":"2024011922220674000_bib21","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1365-2516.2008.01948.x","article-title":"Haemophilia care in adolescents--compliance and lifestyle issues","volume":"15","author":"Petrini","year":"2009","journal-title":"Haemophilia"},{"issue":"6","key":"2024011922220674000_bib22","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1111\/hae.12470","article-title":"Similar bleeding phenotype in young children with haemophilia A or B: a cohort study","volume":"20","author":"Clausen","year":"2014","journal-title":"Haemophilia"},{"issue":"3","key":"2024011922220674000_bib23","first-page":"430","article-title":"Microplate coagulation assays","volume":"13","author":"Pratt","year":"1992","journal-title":"Biotechniques"},{"issue":"14","key":"2024011922220674000_bib24","doi-asserted-by":"crossref","first-page":"3092","DOI":"10.1182\/blood-2009-02-203661","article-title":"Fucosylated chondroitin sulfate inhibits plasma thrombin generation via targeting of the factor IXa heparin-binding exosite","volume":"114","author":"Buyue","year":"2009","journal-title":"Blood"},{"issue":"1","key":"2024011922220674000_bib25","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1182\/blood-2010-08-300756","article-title":"Zymogen-like factor Xa variants restore thrombin generation and effectively bypass the intrinsic pathway in\u00a0vitro","volume":"117","author":"Bunce","year":"2011","journal-title":"Blood"},{"issue":"8","key":"2024011922220674000_bib26","doi-asserted-by":"crossref","first-page":"3234","DOI":"10.1182\/blood-2008-01-136820","article-title":"The heparin-binding exosite of factor IXa is a critical regulator of plasma thrombin generation and venous thrombosis","volume":"112","author":"Buyue","year":"2008","journal-title":"Blood"},{"issue":"4628","key":"2024011922220674000_bib27","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1126\/science.6648524","article-title":"Monoclonal antibodies to a synthetic fibrin-like peptide bind to human fibrin but not fibrinogen","volume":"222","author":"Hui","year":"1983","journal-title":"Science"},{"issue":"6","key":"2024011922220674000_bib28","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1161\/ATVBAHA.111.225334","article-title":"In\u00a0vivo fluorescence imaging of large-vessel thrombosis in mice","volume":"31","author":"Cooley","year":"2011","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"8","key":"2024011922220674000_bib29","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1182\/blood-2009-10-246686","article-title":"The Kunitz-3 domain of TFPI-alpha is required for protein S-dependent enhancement of factor Xa inhibition","volume":"116","author":"Ndonwi","year":"2010","journal-title":"Blood"},{"issue":"1","key":"2024011922220674000_bib30","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1161\/ATVBAHA.113.302655","article-title":"Protein S is a cofactor for platelet and endothelial tissue factor pathway inhibitor-alpha but not for cell surface-associated tissue factor pathway inhibitor","volume":"34","author":"Wood","year":"2014","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2024011922220674000_bib31","first-page":"27","article-title":"New developments in the management of moderate-to-severe hemophilia B","volume":"7","author":"Nazeef","year":"2016","journal-title":"J\u00a0Blood Med"},{"issue":"5","key":"2024011922220674000_bib32","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1055\/s-0030-1255444","article-title":"Recombinant factor IX for clinical and research use","volume":"36","author":"Monahan","year":"2010","journal-title":"Semin Thromb Hemost"},{"issue":"11","key":"2024011922220674000_bib33","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1089\/hum.2017.167","article-title":"Advances in gene therapy for hemophilia","volume":"28","author":"Nathwani","year":"2017","journal-title":"Hum Gene Ther"},{"key":"2024011922220674000_bib34","first-page":"88","article-title":"Advances in gene therapy for hemophilia","volume":"45","author":"Robles-Rodriguez","year":"2020","journal-title":"J\u00a0Biosci"},{"issue":"9","key":"2024011922220674000_bib35","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1177\/2040620718796429","article-title":"Practical aspects of extended half-life products for the treatment of haemophilia","volume":"9","author":"Lambert","year":"2018","journal-title":"Ther Adv Hematol"},{"issue":"1","key":"2024011922220674000_bib36","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1080\/03007995.2019.1662675","article-title":"Assessing bleeding rates, related clinical impact and factor utilization in German hemophilia B patients treated with extended half-life rIX-FP compared to prior drug therapy","volume":"36","author":"Oldenburg","year":"2020","journal-title":"Curr Med Res Opin"},{"issue":"5","key":"2024011922220674000_bib37","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1097\/MOH.0000000000000364","article-title":"Targeting activated protein C to treat hemophilia","volume":"24","author":"Polderdijk","year":"2017","journal-title":"Curr Opin Hematol"},{"issue":"6","key":"2024011922220674000_bib38","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1111\/jth.15270","article-title":"Targeting of antithrombin in hemophilia A or B with investigational siRNA therapeutic fitusiran-results of the phase 1 inhibitor cohort","volume":"19","author":"Pasi","year":"2021","journal-title":"J\u00a0Thromb Haemost"},{"issue":"10386","key":"2024011922220674000_bib39","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1016\/S0140-6736(23)00514-7","article-title":"Fitusiran in haemophilia: a breakthrough drug with many unknowns","volume":"401","author":"Peyvandi","year":"2023","journal-title":"Lancet"},{"issue":"22","key":"2024011922220674000_bib40","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1182\/blood.2019001542","article-title":"Subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A\/B with inhibitors: phase 2 trial results","volume":"134","author":"Shapiro","year":"2019","journal-title":"Blood"},{"issue":"3","key":"2024011922220674000_bib41","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/nrd.2016.199","article-title":"Aptamers as targeted therapeutics: current potential and challenges","volume":"16","author":"Zhou","year":"2017","journal-title":"Nat Rev Drug Discov"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/2\/441\/2210575\/blooda_adv-2023-010819-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/2\/441\/2210575\/blooda_adv-2023-010819-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,19]],"date-time":"2024-01-19T22:22:29Z","timestamp":1705702949000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/2\/441\/498167\/Protein-S-antibody-as-an-adjunct-therapy-for"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,12]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,1,23]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023010819","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,12]]}}}